Nurix Therapeutics, Inc. NRIX Debt Securities, Available-for-Sale, Unrealized Loss Position
Debt Securities, Available-for-Sale, Unrealized Loss Position at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position?
- Nurix Therapeutics, Inc. (NRIX) reported debt securities, available-for-sale, unrealized loss position of $151.57M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position changed year-over-year?
- Nurix Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position increased by 61.3% year-over-year, from $93.94M to $151.57M.